Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.

@article{Wissing2013Radium223CE,
  title={Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.},
  author={Michel Wissing and Fijs W B van Leeuwen and Gabri van der Pluijm and Hans Gelderblom},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 21},
  pages={5822-7}
}
The treatment scope for patients with metastatic castrate-resistant prostate cancer (mCRPC) is rapidly expanding. On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium-223 chloride ((223)RaCl2) for the treatment of mCRPC patients whose metastases are limited to the bones. Radium-223 is an α-emitting alkaline earth metal ion, which, similar to calcium ions, accumulates in the bone. In a phase III study (ALSYMPCA), mCRPC patients with bone metastases received best standard… CONTINUE READING